Evidence map›Paper›PMID 39605494›Full record

ArticlebioRxiv : the preprint server for biology2024

Coordinated protein modules define DNA damage responses to carboplatin at single cell resolution in human ovarian carcinoma models.

Jacob S Bedia, Ying-Wen Huang, Antonio Delgado Gonzalez, Veronica D Gonzalez, Ionut-Gabriel Funingana, Zainab Rahil, Alyssa Mike, Alexis Lowber, Maria Vias, Alan Ashworth and 2 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Jacob S BediaDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-1599-8865
Ying-Wen HuangDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Antonio Delgado GonzalezDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-4760-8174
Veronica D GonzalezBaxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ionut-Gabriel FuninganaDepartment of Oncology, University of Cambridge, Cambridgeshire, UK.ORCID 0000-0002-1197-2652
Zainab RahilBaxter Laboratory for Stem Cell Biology, Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alyssa MikeDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Alexis LowberDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Maria ViasCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, CB2 0RE, UK.ORCID 0000-0003-4955-0102
Alan AshworthHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, 1450 Third Street, San Francisco, CA 94158, USA.ORCID 0000-0003-1446-7878
James D BrentonCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, Cambridgeshire, CB2 0RE, UK.ORCID 0000-0002-5738-6683
Wendy J FantlDepartment of Urology, Stanford University School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0003-3452-7292

Funding

Using a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5M
Role of the microenvironment in ovarian cancer metastasisR01CA234553 · NCI · WASHINGTON UNIVERSITY · PI FUH, KATHERINE CYNTHIA · 2019 to 2023
$2.1M
(PQ8) Biomarker identification by mass cytometry in peripheral blood of patients with renal cell carcinoma undergoing immune checkpoint therapyR21CA231280 · NCI · STANFORD UNIVERSITY · PI FANTL, WENDY JANE, LEPPERT, JOHN THOMAS · 2019 to 2020
$377k
NCI NIH HHS R01 CA234553NCI NIH HHS R21 CA231280NIAID NIH HHS U19 AI057229
6 · The paper itself

Abstract

Tubo-ovarian high-grade serous carcinoma (HGSC) is the most lethal gynecological malignancy and frequently responds to platinum-based chemotherapy because of common genetic and somatic impairment of DNA damage repair (DDR) pathways. The mechanisms of clinical platinum resistance are diverse and poorly molecularly defined. Consequently, there are no biomarkers or medicines that improve patient outcomes. Herein we use single cell mass cytometry (CyTOF) to systematically evaluate the phosphorylation and abundance of proteins known to participate in the DNA damage response (DDR). Single cell analyses of highly characterized HGSC cell lines that phenocopy human patients show that cells with comparable levels of intranuclear platinum, a proxy for carboplatin uptake, undergo different cell fates. Unsupervised analyses revealed a continuum of DDR responses. Decompositional methods were used to identify eight distinct protein modules of carboplatin resistance and sensitivity at single cell resolution. CyTOF profiling of primary and secondary platinum-resistance patient models shows that a complex DDR sensitivity module is strongly associated with response, suggesting it as a potential tool to clinically characterize complex drug resistance phenotypes.

Identifiers

PMID39605494
PMCPMC11601625

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.